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Biomedical applications at high-energy particle accelerators have always been an
important section of the applied nuclear physics research. Several new facilities are
now under constructions or undergoing major upgrades. While the main goal of these
facilities is often basic research in nuclear physics, they acknowledge the importance of
including biomedical research programs and of interacting with other medical accelerator
facilities providing patient treatments. To harmonize the programs, avoid duplications,
and foster collaboration and synergism, the International Biophysics Collaboration is
providing a platform to several accelerator centers with interest in biomedical research.
In this paper, we summarize the programs of various facilities in the running, upgrade, or
construction phase.
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INTRODUCTION
Particle accelerators have provided an extensive contribution to research beyond particle and
nuclear physics. Astrophysics, atomic physics, plasma physics, materials research, environmental
science, archaeometry, homeland security, space radiation research, biology, and medicine largely
use and benefit from particle accelerators [1]. Biomedical applications are particularly important,
for their impact on societal health [2]. One of the main medical applications of accelerators is
certainly the production of radioisotopes to be used for imaging, therapy, or both (theranostics)
[3–5]. Accelerators also spawned charged-particle therapy, a technique for cancer treatments that
exploits the Bragg peak of charged particles and can reduce toxicity and improve local control
compared to conventional X-ray radiotherapy [6]. Fast neutrons have been used in the past for
cancer therapy but then dismissed because of inacceptable toxicities [7]. Epithermal and thermal
neutrons can, however, effectively kill tumors loaded with 10B, the so-called boron-neutron capture
therapy (BNCT) [8, 9]. BNCT has been hampered by the necessity of using nuclear reactors
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for treatment but is now revived by the perspective of using
dedicated proton accelerators [10]. Cyclotrons and synchrotrons
for charged-particle therapy are blooming worldwide [11–13],
and many of these centers have intense preclinical research
programs [14]. Research in space radiation protection also needs
accelerators to simulate the cosmic radiation that astronauts find
in the space environment [15–19]. In fact, most of our knowledge
on radiation risk in space comes from experiments at particle
accelerators [20, 21].
Many new large-scale accelerators are under construction
worldwide, with the primary goal of basic research in nuclear
physics, generally exploring the region far from stability [22].
Most of the accelerators centers have ambitious biomedical
research programs that are innovative and potentially can lead
to breakthrough discoveries thanks to the characteristics of
the new facilities, generally with higher intensity and energy
than current accelerators have [23]. Figure 1 shows some of
the opportunities that can exploit the characteristics of new
accelerators or the upgrade of existing facilities. High energy
is obviously important for space radiation research, because
cosmic rays have energies up to TeV [24, 25] but can also be
useful for particle radiography [26], an important technique
to reduce range uncertainty in particle therapy. High intensity
can potentially be a major breakthrough in particle therapy:
ultrafast treatments are convenient for patient welfare and for
clinical workflow and can mitigate the problem of moving
targets [27]. Recent results with electron beams suggest that dose
rates exceeding 40 Gy/s reduce toxicity in the normal tissue
while maintaining tumor local control (FLASH radiotherapy)
[28, 29]. High intensity is also useful for spatially fractionated
radiotherapy using protons [30] or heavier ions [31], a method
that largely reduces normal tissue toxicity in animal models
[32–34]. Finally, radioactive ion beams (RIB), one of the main
nuclear physics topics that justify the construction of new nuclear
physics facilities [35], are potentially an extraordinary tool for
therapy as they allow the online visualization of beams during
irradiation [36].
While all these research programs are exciting, it is
important to avoid duplications, exploit synergism, and foster
collaborations and strong links between clinical accelerators
and nuclear physics accelerators planning applied biomedical
research. For these reasons, many facilities have joined the
International Biophysics Collaboration [37] that had a first
meeting in Darmstadt in May 2019 [38]. Here, we present the
biomedical research programs of several accelerator facilities that
have joined the Biophysics Collaboration.
BIOMEDICAL RESEARCH PROGRAMS AT
PARTICLE ACCELERATORS
Fair
The Facility for Antiprotons and Ion Research (FAIR) is currently
under construction in Darmstadt [39]. As shown in Figure 2,
the current SIS18 synchrotron (18 Tm) at GSI will become the
injector of the new SIS100 (100 Tm) ring. All ions from H to U
can be accelerated up to around 10 GeV/n. FAIR will also reach
intensities up to ×10,000 higher than those currently available
at GSI, and this intensity upgrade is already ongoing at SIS18
in the framework of the so-called FAIR-phase-0 [40]. While the
official opening of the SIS100 is slated for 2017, research is
currently ongoing within the FAIR-phase-0. Research activity at
FAIR is structured into four pillars: NuSTAR, CBM, PANDA,
and APPA. APPA deals with applied research (biophysics and
materials research) and atomic and plasma physics [41]. FAIR is
a user facility, and research is proposed by collaborations. The
Biophysics Collaboration is indeed based at FAIR1 but, unlike
other collaborations, includes other accelerator facilities, and
aims at a distributed research program.
The biophysics research program at FAIR imposes on the
exceptional experience of the Biophysics Department in both
heavy-ion therapy and space radiation research [Kraft et al.
submitted]. In fact, GSI was the first center in Europe to treat
patients with accelerated 12C ions [42] and is currently the
reference center of ESA for the ground-based research program
[16] called IBER2. With the end of the therapy in 2007, GSI
activity focused on heavy-ion basic research, with applications
to therapy and space radiation protection. Research at FAIR
will therefore continue in these directions, according to the
new opportunities that the SIS100 energies and the upgraded
intensities offer (Figure 1). The new research programs include
the construction of a galactic cosmic ray simulator [43], high-
energy particle radiography [44], FLASH irradiations with heavy
ions [45], and testing of carbon and oxygen radioactive isotopes
for therapy and simultaneous imaging by PET [36], a program
that has been supported by a recent ERC Advanced Grant
(BARB)3. The Biophysics Department will benefit from FAIR
with a new experimental vault, the APPA cave (Figure 3), where
especially high-energy space radiation protection experiments
will be performed.
NICA
The Nuclotron-based Ion Collider fAcility (NICA) is a new
accelerator facility designed at the Joint Institute for Nuclear
Research (JINR, Dubna, Russia) to study properties of dense
baryonic matter [46, 47]. The NICA facility (Figure 4)
includes the injection complex, a new superconducting
booster synchrotron, the existing modernized superconducting
heavy-ion synchrotron “Nuclotron,” a new collider with two
superconducting storage rings and with two interaction points
[one for heavy-ion studies with the multipurpose detector
(MPD) and another for polarized beams for the spin physics
detector (SPD) experiment], an electron cooling system, new
beam transfer channels, and the experimental zone for extracted
beams with a Baryonic Matter at Nuclotron (BM@N) detector.
The main goal of the project is the study of hot and dense
strongly interacting matter in heavy-ion (up to Au) collisions.
A study of spin physics with extracted and colliding beams of
polarized deuterons and protons is also planned. Gold ions will
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FIGURE 1 | Radiation research at accelerators. The shaded region includes values of energy and intensities covered by the present accelerators. MBRT, minibeam
radiotherapy; RIB, radioactive ion beams; FLASH, high-dose-rate radiotherapy.
FIGURE 2 | Layout of the FAIR facility under construction in Darmstadt (Germany).
protons, up to 12.6 GeV. Two modes of operation are foreseen:
collider mode and extracted beams. The proposed program
allows one to search for possible signs of phase transitions and
critical phenomena as well as to shed light on the problem
of the nucleon spin structure. For applied physics research,
three new experimental areas are planned. Topics of interest
are radiobiology and particle therapy, cosmic ray simulation,
radiation hardness of electronic devices, novel technologies in
materials science, and nuclear energetics. Ion beams with an
energy of 250–800 MeV/u extracted from Nuclotron will be
used for these experiments. The commissioning of beamlines
and experimental stations for applied research as a part of basic
NICA configuration is expected in 2022.
The biomedical research program carried out by the
Laboratory of Radiation Biology (LRB) at the NICA complex
will be focused on studying heavy-ion action at the molecular,
cellular, tissue, and organism levels of biological organization.
Primary attention will be paid to research on experimental
animals’ central nervous system (CNS) disorders because the
CNS must be considered a critical system when evaluating the
Frontiers in Physics | www.frontiersin.org 3 October 2020 | Volume 8 | Article 380
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FIGURE 3 | Beamline for BIOMAT applications in the APPA cave at FAIR.
FIGURE 4 | Layout of the NICA facility under construction in Dubna (Russia).
radiation exposure risk for the interplanetary mission crews and
considering the possible side effects of the radiotherapy of brain
tumors. The main advantage of LRB and NICA is an excellent
opportunity to perform large-scale in vivo animal exposures in
collaboration with leading Russian experts in this field, who
have all the necessary licenses. The research on rodents includes
behavioral studies, pathomorphological studies of irradiated
brain structures with the aim of modern immunohistochemical
methods and morphometry, cytogenetics, and neurochemical
and electrophysiological studies. Worldwide unique experiments
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on primates for the estimation of radiation risks of CNS
disorders and carcinogenesis are in progress at the LRB. The
LRB also develops a hierarchy of mathematical models to
simulate radiation-induced pathologies at different organization
levels and time scales. In addition to the traditional Monte
Carlo technique, the LRB’s approach involves computational
methods from different knowledge areas (molecular dynamics
and simulation of brain neural networks). The radiation research
program at NICA can contribute to a better reproduction of the
space environment. The LRB has proposed a novel Nuclotron-
based technique of modeling radiation fields with continuous
particle energy spectra generated by galactic cosmic rays inside
spacecraft in deep space.
A huge amount of experimental work has to be done
at accelerators worldwide to understand how heavy charged
particles may disturb the CNS performance after cancer therapy
or during space flights. Certainly, there is a strong need for broad
international collaboration in this field.
iThemba Labs
With more than 30 years of operation of the separated
sector cyclotron, the iThemba Laboratory for Accelerator Based
Sciences (LABS) is the largest facility for accelerator-based
sciences in the southern hemisphere. It is one of the research
infrastructure platforms of the National Research Foundation
(NRF) in South Africa, with the main goals of supporting
research of strategic importance, training the future research
workforce, and providing access to unique infrastructure for
national and international users.
The facility has a long history and expertise in radiation
biophysics research, which went hand in hand with the start of
the particle therapy program in 1988 with a 66 MeV p + Be
isocentric neutron therapy system and a fixed 200 MeV proton
therapy facility [48]. In the first decades, the research program
was dominated by clinical research and the development and
optimization of particle therapy treatment modalities. Today, the
new Radiation Biophysics Division is driving a multidisciplinary
research program that converges the existing expertise in the
field of radiation biology and medical physics, to investigate
the relationship between radiation quality and biological effects.
Researchers can make use of the well-characterized 200 MeV
proton beamline, as well as the neutron beamlines available at
iThemba LABS. The latter includes a rather unique quasi mono-
energetic neutron metrology beamline, with beam energies
ranging from 30 to 200 MeV, using (p, n) reactions on thin Li
and Be targets [49]. Currently, very little information is available
on the biological effects of high-energy neutrons (>20 MeV)
that are most pertinent to applications in civil aviation, future
manned space missions, and particle therapy. Therefore, the
well-characterized neutron fields at iThemba LABS will be of
growing importance in the coming years, to fill this gap in
an attempt to decrease the existing uncertainties on neutron
weighting factors and the relative biological effectiveness at
higher neutron energies.
Next to research projects with external particle beams, there is
a growing interest in radioisotope research. This is attributable
to the launch of the South African Isotope Facility (SAIF) at
iThemba LABS in 2019, which includes the acquisition of IBA’s
Cyclone R© 70 cyclotron (Figure 5) [50, 51]. The advent of the new
70 MeV cyclotron at iThemba LABS will not only increase South
Africa’s radioisotope production capacity but will also boost
research into new solutions for nuclear medicine applications.
This will be achieved through the optimization of isotope
production processes, research in radiochemistry, radiolabeling,
and preclinical radiobiological studies on newly developed
radiopharmaceuticals. In the coming years, a strong focus will go
to the development of new theranostic radiopharmaceuticals and
the production of astatine-211, a promising isotope for targeted
α-particle therapy [52].
On the one hand, the research program of the Radiation
Biophysics Division at iThemba LABS can be summarized in
cancer detection and therapy projects, with a main focus on
radioisotopes and particle therapy. This comprises studies on
systemic effects and the tumor microenvironment, such hypoxia
and tumor angiogenesis. On the other hand, there is a set of
research projects linked to radiation protection, which includes
biological dosimetry projects and the implementation and
validation of the first ground-based setup for space radiobiology
research in Africa. For all projects, microdosimetry and Monte
Carlo simulations remain vital tools, in order to assess the
microscopic patterns of energy deposition by radiation, which
ultimately govern the observed biological effects [53]. Lastly,
the location of iThemba LABS provides the advantage to
conduct projects that are unique to Africa, including studies on
potential inter-ethnic differences in radiation sensitivity and the
cancer resistance of large long-living mammals, such as African
elephants [54].
The SAIF project at iThemba LABS, as outlined in Figure 5,
is designed in two phases. Phase 1 consists of a radioisotope
facility with four production targets and the initial phase (phase
0) of the Low Energy Radioactive Ion Beam (LERIB) facility.
Here, the high-intensity proton beam from the SSC (up to 250
µA) will be used as a driver for the Isotope Separation On-Line
(ISOL) production of radioactive isotopes of special interest in,
for example, the study of neutron-rich nuclei involved in the r-
process. Phase 2 will comprise the building of a new driver for
the production of RIB, based on a high-intensity electron beam
and the photo-fission method for the production of neutron-rich
exotic isotopes which will be used as higher-intensity low-energy
RIB but also accelerated high-intensity RIB using the SSC as
a post-accelerator.
HIMAC
In the National Institute of Radiological Sciences (NIRS), carbon
ion radiotherapy has been conducted since 1994 using the
Heavy-Ion Medical Accelerator in Chiba (HIMAC). During the
past 25 years, this radiotherapy has been applied to various
tumors, and the optimum dose-fractionation protocols have been
developed for these tumors through dose-escalation clinical trials
[55–58]. To date, more than 12,000 patients have been treated
with the HIMAC. Besides the clinical studies, various physical
studies have been conducted to develop new treatment methods
and devices such as respiratory gating [59], layer stacking
[60], 3D pencil beam scanning [61], and a superconducting
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FIGURE 5 | Layout of the main facility at iThemba LABS and its future developments. SAIF phase 1 includes phase 0 of the LERIB facility (shaded in pink) and the
new 70 MeV cyclotron with its target stations (shaded in blue). The second phase of the project includes the installation of a Rhodotron in the area shaded in yellow for
the production of radioactive ion beams (RIB).
rotating gantry [62]. For further development of charged-particle
therapy, the NIRS initiated a new research project referred to
as “Quantum Scalpel.” The Quantum Scalpel consists mainly
of two research topics. The first topic is downsizing and cost
reduction of the treatment facility. By combining high-power
laser and superconducting magnet technologies, the facility
size will be reduced to ∼1/6 that of the HIMAC, i.e., 20 ×
10 m2. The second topic is maximizing the clinical effects
and minimizing the treatment period. For this, researchers
in the Department of Accelerator and Medical Physics are
developing a hypo-fractionatedmulti-ion radiotherapy (HFMIT)
in which several ion species are delivered in one treatment
session to optimize the dose and linear energy transfer (LET)
distributions simultaneously [63]. Clinical trials of the HFMIT
will start in 2022 following a series of commissioning tests. In
other projects, emerging technologies such as immunotherapy,
magneto-particle therapy [64], and FLASH radiotherapy [29]
have been found to show enhanced novel effects with charged-
particle beams. Investigations at the NIRS continue on all of
these technologies.
GANIL and MI2B
The largest facility for nuclear physics in France located in
Caen is jointly run by CEA and CNRS. GANIL as well as
its major upgrade SPIRAL2 (Figure 6) is engaged in research
with ion beams with the main focus of the laboratory
being fundamental nuclear physics. This is supplemented by
strong programs in accelerator-based atomic physics, condensed
matter, radiobiology, and industrial applications. The intensity
and variety of beams delivered by the cyclotrons and the
superconducting linear accelerator and the associated state-of-
the-art scientific instruments make GANIL-SPIRAL2 a unique
and outstanding multidisciplinary facility [65]. GANIL-SPIRAL2
is the only facility in the world today which provides high-
intensity stable beams, beams of short-lived nuclei (RIB)
produced both by the ISOL technique and by the in-flight
separation technique and intermediate energy neutron beams
[66]. The large heavy-ion accelerator complex of five cyclotrons
delivers stable beams (carbon to uranium) from energies
around 1–95 MeV per unit mass with current up to 10 µA.
Fragmentation beams range from light to medium mass nuclei.
The reaccelerated beams produced using SPIRAL1 beams range
from 1.2 to 25 MeV/A for around 35 isotopes today. A new ion
source has been commissioned, so more new RIB for different
elements are available, and more will be available4 in the near
future. The new superconducting LINAC will provide the most
intense beams from protons to Ni up to 14.5 MeV per unit mass.
Continuous and quasi-mono-energetic beams of neutrons will be
available. The flux at NFS will be up to 2 orders of magnitude
higher than those of other existing time-of-flight facilities for a
part spectrum in the 1–40 MeV range. The latter will open new
and unique avenues.
Materials science research at GANIL is studied using
a large range of energies and beams along with versatile
4https://www.ganil-spiral2.eu/scientists/ganil-spiral-2-facilities/available-beams/
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FIGURE 6 | Layout of the GANIL-SPIRAL2 facility in Caen (France).
tools. High-energy ions provide quality beams for studies
on nanostructuration of selective membranes and sensor
developments based on topical 2D materials (graphene, MoS2,
etc.). Exploiting time/depth-resolved characterizations to their
limit, the sensitivity of functional inorganic materials to dense
electronic excitations is studied. Advanced experimental setups
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also provide in situ analysis for organic polymers (CESIR
or CASIMIR) or astro-ices (IGLIAS) as simulators for alpha
radiation, cosmic rays, or solar winds.
The relevant biomedical activities span a variety of topics.
Measurements of double differential cross section for charged
particles with 95 MeV/A C beams on targets of various elements
that are relevant to hadron therapy were performed. Irradiation
and hardening of electronic components for space are performed
using heavy and energetic ions. The studies include single-event
effect (SEE) to improve the architectures and define testing
standards used in space. Dedicated equipment for irradiation
of polymeric films allow industrial production with various ion
track densities and ultimately very fine and uniform filters. The
LARIA center at GANIL studies various aspects related to the
study and understanding of the biological effects related to direct
and indirect (bystander) impacts by carbon beams in cancer
treatment. The topics range from understanding differential
cellular responses of radioresistant tumors to conventional
radiotherapy and hadrontherapy to exploring the fundamental
mechanisms of communication between irradiated and normal
cells, etc. The facilities for these activities include cell culture
room, two sterile hoods, four CO2 incubators, a microscope,
water baths, centrifuges, etc. All the above activities are run at
the cyclotrons. Light-ion beams from the LINAC, like alpha and
6,7Li beam on Pb and Bi targets, will be used to perform R&D on
the production of innovative radioelements for nuclear medicine
and in particular alpha emitters. This will consist in cross-section
measurements to determine the optimum energies maximizing
the cross section for the nuclei of interest (e.g., the promising
211At) [67] while minimizing those for nearby contaminants
(210At and 209,210Po in the case of 211At); to develop high-
power target stations to sustain the very high beam current from
the new LINAC; and to find new and promising production
routes. The NFS facility can be used for irradiation of cells,
for characterization of detectors, and also for the study of the
single-event defects.
In France, several irradiation facilities for biomedical
applications are being coordinated by CNRS within the so-
called “Groupement de Recherche MI2B.”5 MI2B animates a
national network of clinical-based and academic research-based
irradiation facilities called ResPlanDir, dedicated to dosimetry,
instrumentation, and radiobiology, by supporting harmonization
of practices. Among the various irradiation modalities, one
should mention the availability of a complete panel of proton and
light-ion irradiation platforms: AIFIRA at CENBG-Bordeaux6
proposes up to 3.5 MeV proton or alpha particle microbeams
(size of typically 1.5µm FWHM in air) equipped with an online
microscope. This makes possible the selective irradiation of
single-layered cells. CYRCé at IPHC-Strasbourg7 is a combined
platform for radioisotope production working for academic




with energy ranging from keV to 24 MeV8 for cell or small-
animal irradiation (possibility to tune a spread-out Bragg peak
up to 6mm), a biological laboratory with small animals, and
preclinical imaging (PET and SPECT). The ARRONAX facility9
is a combined research and innovative radioisotope production
facility, delivering protons (35 and 70 MeV), deuterons (15
and 35 MeV), and alpha particles (70 MeV). A dedicated
experimental irradiation room (Figure 7) has been equipped for
physics and materials science experiments and cell irradiation by
means of a vertical beamline.
INFN and CNAO
The National Institute for Nuclear Physics (INFN) in Italy
has several accelerator facilities with biomedical applications,
including Laboratori Nazionali del Sud (LNS) in Catania [68],
the first center in Italy to treat patients with proton therapy for
eye tumors, and the Trento Institute for Fundamental Physics
and Applications (TIFPA), where an experimental vault [69] with
two beamlines delivering protons with energies up to 230 MeV
is available in the local proton therapy center, where two other
rooms are equipped with isocentric gantries for treating patients.
The INFN National Laboratories of Legnaro (LNL) are
devoted to the study of fundamental nuclear physics and
astrophysics together with the development of technologies
relevant to these disciplines. Ever since its foundation, LNL has
carried out a significant applied physics research, developing very
relevant programs in the biomedical field with the existing LNL
accelerators as well as the future SPES facility. Applications of ion
beams in multidisciplinary physics are a long-standing tradition
of LNL. These activities are carried out mainly at the AN200010
and CN11 Van de Graaff accelerators and partly at the Tandem12.
The CN (1–6MV) and AN2000 (0.2–2.2MV) provide a total of
12 beamlines and deliver around 2,700 h/year of beamtime (1H,
2H, 3He, 4He, 14N, and 15N). The main activities at the AN and
the CN in the field of interdisciplinary physics are radiobiology
[70, 71], dosimetry, materials microanalysis with IBA methods,
study of novel neutron detectors based on innovative materials,
single-ion irradiation for quantum technologies, and HpGe, Si,
and diamond detector characterization.
LNL has a very long and strong tradition in the field
of microdosimetry and nanodosimetry [72, Colautti et al.
submitted]. In particular, Legnaro is one of the leading
laboratories for the construction of miniaturized tissue
equivalent proportional counters. Legnaro is in contact with
various radiotherapy centers for the supply of these detectors
or the microdosimetric characterization of therapeutic beams
(Detector/MedAustron, SCK, JINR). These detectors can be
used for quality assurance of treatment planning systems
which include linear energy transfer calculations. In the field of
nanodosimetry, STARTRACK is one of three detectors in the
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FIGURE 7 | Experimental cave at ARRONAX (Nantes, France). AX5 is a vertical irradiation beamline.
the DNA level [73]. It is installed and running at Tandem. A
portable version is under construction.
Selective Production of Exotic Species (SPES)13 is a second-
generation ISOL facility on which the short- and long-
term strategies of the laboratory are centered [74]. It is an
interdisciplinary project, ranging over nuclear physics, nuclear
medicine, and materials science. SPES will provide a RIB facility
for the study of neutron-rich unstable nuclei of interest to nuclear
and astronuclear physics research [75]. At the same time, it will
host a laboratory for research and production of radioisotopes to
be applied in nuclear medicine. SPES is based on a dual-exit high-
current cyclotron, with proton beam energy ranging between
35 and 70 MeV and a maximum beam intensity of 0.75mA,
used as a proton driver to supply an ISOL system with a UCx
Direct Target able to sustain a power of 10 kW and produce
neutron-rich ions at intensities 1 order of magnitude higher than
existing facilities. The second exit will be used for applied physics:
radioisotope production for medicine and neutrons for materials
study. Quasi-mono-energetic neutrons at energies ranging 30–
70 MeV will be produced using a 10mA proton beam at an
expected intensity around 5·105 n·cm−2·s−1 at 3m from the Li
production target. The layout of the facility is shown in Figure 8.
The proton beam from the cyclotron can be sent to two ISOL
target caves (ISOL1 and ISOL2), three caves for radioisotopes
production (RIFAC) and developments (RILAB), and an area for
neutron production and materials study. SPES was designed to
13https://web.infn.it/spes/index.php/home/spe
pursue also the aim of studying the production of innovative
radionuclides for medicine (LARAMED) starting from the
assumption that new radioisotopes may show unprecedented
biological properties. Nonstandard radionuclide production is
a fundamental opportunity for nuclear medicine in order to
identify new radiopharmaceutical classes for diagnostic and
therapeutic applications. RILAB will be dedicated to research
in the field of radioisotopes (cross-section measurements, high-
power target tests, etc.), whereas RIFAC will be devoted to the
production of novel radioisotopes (64Cu, 67Cu, 82Sr, 68Ge, etc.).
In June 2018, the INFN board of directors has approved the
contracts for the supply of beam and the lease of laboratory
space to BEST Theratronics for the commercial production of
radioisotopes, initially using the ISOL2 cave. Also, in the field of
nuclear medicine, the ISOLPHARM project will exploit the ISOL
technique to produce a large variety of carrier-free radioisotopes
with high radionuclidic purity (INFN international patent). The
layout of SPES was designed in such a way as to operate two
targets at the same time, distributing the beam according to a
schedule that minimizes the radiation problems. It should be
considered that the activation of materials at a beam power of 20–
30 kW does not allow operating the same target for a long time.
Considering a shift of 2 weeks with 2 days for beam preparation,
12 days of beam on target, and seven shifts for maintenance, we
can offer about 5,000 h/year of beam dedicated to the ISOL targets
and 5,000 for applications.
INFN has also collaborated on the construction of the
experimental vault for dedicated biomedical research in the
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FIGURE 8 | Layout of the SPES facility under construction in Legnaro (Italy).
National Center for Oncological Hadrontherapy (CNAO) in
Pavia. CNAO [76, 77] is one of the four centers in Europe
in which hadrontherapy is administered with both protons
and carbon ions. The main accelerator is a 25-m-diameter
synchrotron designed to accelerate ions injected at 7 MeV/u up
to the maximum energy corresponding to the magnetic rigidity
of 6.35 Tm. For C6+ ions, this corresponds to 400 MeV/u;
in the case of protons, the maximum available energy of 250
MeV corresponds to a magnetic rigidity of 2.43 Tm, well below
the technically achievable maximum. For other ions that will
be produced with a dedicated third source presently under
construction, the maximum rigidity would still be 6.35 Tm, and
the corresponding particle range would be determined by their
charge and mass.
CNAO has a 2-fold institutional purpose including both
therapy and research, and it also provides great opportunities
to perform various research activities related to radiation
biophysics, radiobiology, space research, and detector
development. For researchers, a dedicated experimental
irradiation room is available in time slots not impacting patients’
treatment but specifically devoted to research purposes (i.e.,
some night shifts and weekends, typically) and, if applicable, in a
parasitic modality during daily treatments, for the experiments in
which the duration is not important and the measurement itself
can be “paused” for an indefinite time. The beam distribution
in the CNAO experimental room is based on the same active
system in use in the treatment rooms. According to the needs of
the experiment to be performed, the experimental beamline can
be arranged in four different configurations depending on the
space required downstream the target or the dimensions of the
scanning field (Figure 9). The beam intensities available range
from the clinical ones (<1010 protons per spill and < 4·108
carbon ions per spill) down to a few particles per second.
CNAO offers the opportunity to external researchers to use
its beams to perform basic and preclinical studies and to take
advantage of a cell culture laboratory for sample preparation and
processing. Thanks to a strong collaboration with the University
of Pavia, in CNAO, it is also possible to carry out in vivo
irradiations with small rodents, taking advantage of the nearby
animal house facility, after technical evaluation and approval
by the local ethical committee. Typical activities carried on
at CNAO are development and test of beam monitors and
of dosimeters, the development of the dose delivery system
to improve the scanning technique (e.g., 4D treatments), the
verification of dose delivered to the target, and of course
radiobiology. The main topics for the present radiobiological
research in CNAO comprise tissue, cell, and molecular
experimental activities aiming to investigate the mechanisms
of response after particle irradiation. In particular, one of the
interests is modulation of the malignant behavior of surviving
tumor cells by reducing or promoting their invasiveness or
migration. Cellular andmolecular mechanisms of radioresistance
after irradiation with carbon ions, immune stimulatory effects
of radiation, and immunosuppressive properties of high-LET
radiations and abscopal effect are also subjects being studied
at CNAO. One hot topic for CNAO radiobiological research
is the evaluation of existing and/or new radiosensitizing agents
with high-LET radiations. Physical amplification of LET by
nuclear interaction, e.g., of protons on boron nuclei is also
being studied.
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FIGURE 9 | The experimental room at CNAO can be arranged in different configurations according to the experiment requirements.
This subject might become even more interesting since
CNAO is willing to build a new boron neutron capture
therapy (BNCT) facility in the next future. At CNAO, the
introduction of an accelerator-based BNCT system is indeed
presently under consideration. This activity will be performed,
strengthening collaborations with INFN, University of Pavia,
and other institutions, since the introduction of BNCT requires
a properly structured multidisciplinary research phase with
distributed skills (medical doctors, radiobiologists, medical
physicists, chemists, etc.). Furthermore, the BNCT needs the
development of biomedical imaging techniques for the mapping
of the biodistribution of compounds enriched in 10B and for the
selection of the ideal time interval of irradiation with thermal
neutrons [78, 79].
HIT
The Heidelberg Ion-Beam Therapy Center (HIT) at the
Hospital of the University of Heidelberg (UKHD) is the
first dedicated and hospital-based particle therapy center in
Europe offering clinical scanned proton and carbon ion beams
[80]. The treatment with helium ions is planned to start
in late 2021, and oxygen beams are offered for preclinical
research. Dose delivery is based on the intensity-controlled
raster scanning method. The maximum field size is 200 × 200
mm2. The first worldwide rotating carbon ion gantry could be
realized at HIT. Today, about 40% of patient treatments are
executed at this unique device that combines robotic patient
positioning, raster scanning dose delivery, and video-based
patient tracking.
HIT has started routine patient treatment at a horizontally
fixed beamline in November 2009. The carbon ion gantry is in
clinical use since October 2012. In total, about 6,200 patients have
been treated at HIT. It is an extension to the already available
oncological methods at the Heidelberg University Hospital and
indirectly complements the existing radiotherapy department
hosting seven electron accelerators including tomotherapy and
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FIGURE 10 | Floor plan of the AGOR accelerator facility with the new infrastructure for image-guided preclinical research.
a gamma knife. In addition to patient care, a broad research
program in the area of radiation oncology and accelerator
physics, medical physics, and biophysics [81–83], annually using
about 1,000 h of beamtime, is pursued at HIT. Large-scale clinical
studies in the field of ion beam therapy as well as methodological
studies are conducted here [84].
HIT operates an irradiation facility for preclinical research
that delivers four ion species: protons and helium, carbon, and
oxygen ions. HIT’s accelerator system provides energies up to
430 MeV/u for helium, carbon, and oxygen ions and up to 480
MeV for protons. For all ions, energy libraries are established
that allow for millimeter-range steps within the therapeutic
window (Bragg peak depth between 2 and 32 cm in water). For
protons and helium ions, higher ranges/energies can be offered
for research purposes. Within the center, laboratories for medical
physics and experiment preparation as well as a dedicated rodent
housing are located directly at the research cave. Laboratories for
radiobiology are hosted in the attached building for conventional
radiation therapy.
KVI-CART
The core of the accelerator facility at the KVI-Center for
Advanced Radiation Technology (KVI-CART), University of
Groningen (UG), the Netherlands, is the superconducting
cyclotron AGOR [85], built in collaboration with the Institut
de Physique Nucléaire (Orsay, France) and operational in
Groningen since 1996. It accelerates ion beams of all elements
to a variable energy. Initially designed for research in nuclear
physics and fundamental interactions, the focus of the research
at the facility has, in relation with the establishment of a
clinical proton therapy clinic at the University Medical Center
Groningen (UMCG), in recent years shifted toward the radiation
physics and biology of particle therapy.
Access to the facility is governed by the guidelines set out in
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TABLE 1 | A comparison of the accelerator facilities in the Biophysics Collaboration.
Name Status Location Accelerator Ions Maximum energy
FAIR Under construction (starts 2025) Darmstadt, Germany Synchrotron (100 Tm) H to U ∼10 GeV/n
GSI In operation in FAIR-phase-0 Darmstadt, Germany Synchrotron (18 Tm) H to U ∼1 GeV/n
NICA Under construction Dubna, Russia Synchrotron Up to Au Up to 4.5 GeV/n for Au, up to 800
MeV/n for biomedical applications
iThemba In operation; under upgrade Cape Town, South Africa Cyclotron H 200 MeV. A 70 MeV cyclotron will be
used for isotopes
HIMAC In operation Chiba, Japan Synchrotron He to Fe ∼400 MeV/n for C-ions
GANIL In operation Caen, France Cyclotrons H to U 95 MeV/n
MI2B In operation France Network of different
small accelerators
H, He ∼70 MeV
SPES Under construction at LNL-INFN Legnaro, Italy Cyclotron H 70 MeV
LNS-INFN In operation; under upgrade Catania, Italy Cyclotron H to Au 80 MeV/n (H to Ne), 50 MeV/n (Au)
CNAO In operation Pavia, Italy Synchrotron H and C 250 MeV (H), 400 MeV/n (C)
HIT In operation Heidelberg, Germany Synchrotron H, He, C, and O 480 MeV (H), 430 MeV (He to O)
KVI-CART In operation Groningen, The Netherlands Cyclotron H to Pb 190 MeV (H), 90 MeV/n (He to O), 75
MeV/n (Ne)
Highlighted in yellow are the facilities with clinical operation.
Since 1998, research on normal tissue damage in radiotherapy is
performed in collaboration with the RadiationOncology and Cell
Biology departments of the UMCG. The experiments use mainly
proton and carbon beams and have two main focal points: in vivo
studies of non-local effects in (partial) irradiations of organs such
as parotid [86], heart–lung system [87, 88], and neural tissues [89]
and in vitro studies of various aspects of the radiation response of
stem cells [90, 91].
For this research, a versatile, modular beamline [92] has been
built that is also used for experiments in medical radiation
physics and for radiation hardness testing with both protons
and various heavy ions. The on-site laboratory facilities for the
radiation biology research comprise an animal accommodation
for wild-type rodents and two laboratories equipped with
CO2 incubators and flow cabinets. In the coming years, the
capabilities and capacity for radiation biology research will
be substantially expanded. Currently, an additional beamline
specifically for in vivo studies, equipped with 3D X-ray and
bioluminescence imaging and 2D proton radiography at the
irradiation position and funded by the Dutch cancer society
KWF, is under development. In Figure 10, the floor plan of
the accelerator facility, showing both the existing beamline for
biomedical experiments and the new beamline, is displayed.
With this new infrastructure, among others, more detailed
studies of the spatial differentiation of the radiation response
of normal and tumor tissues, interaction between particle
irradiation, and systemic therapy, and biological effectiveness will
be performed. At this new beamline, small animal irradiations
will be performed with proton and helium beam as well as X-
rays using different irradiation modalities. Besides the shoot-
through method [89] employing 150–190 MeV protons, spread-
out Bragg peak irradiations using primary beam energies up to 90
MeV/amu (range in water at 60mm for both protons and helium)
can also be performed. Both passive scattering and pencil beam
scanning will be available, and the irradiations can be CW or
pulsed with variable pulse duration (≥ 10 µs) and a frequency
of up to 2 kHz. The design calculations for the beamline indicate
that pencil beams with 0.5mm FWHM are feasible. Based on
preliminary experiments, local dose rates up to at least 1,000 Gy/s
should be achievable for both proton and helium irradiations in
pencil beam scanning.
In conjunction with this new infrastructure, additional animal
accommodations with associated laboratories will be built
to provide optimal research conditions. The capacity of the
laboratories for in vitro research will also be expanded. A setup
for live-cell confocal microscopy immediately after irradiation is
under development in collaboration with Amsterdam UMC.
To facilitate the use of the new infrastructure by external users,
we will, in collaboration with the central animal research facility
of UG and UMCG, offer a “one stop shop” service. Based on
the detailed experiment design developed in collaboration with
the users, we will arrange the required Dutch authorizations,
procure the required animals, perform the irradiations, and,
when desired by the user, perform the post-irradiation follow-
up experiments. The data will be provided to the users
through a research data management platform controlled by
the users.
The current radiation physics research by both internal and
external users focuses on near-real-time in vivo range verification
in particle therapy [93, 94] and various aspects of dosimetry,
including characterization of the LET distribution of particle
beams [95] and tissue relative stopping powers [96].
CONCLUSIONS
Biomedical research programs at particle accelerators cover
a vast range of topics such as particle therapy, radioisotope
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production for medicine, and radioprotection in space. Along
with accelerator facilities with long tradition, there are several
new accelerators now under construction that can enrich the
nuclear physics weaponry for biological and medical research
(Table 1). Collaboration is a key point to exploit the translational
potential of these researches and maximize the benefit for
patients. Only a strong network of different centers can exploit
synergies, avoid duplications, and raise the quality and the impact
of biomedical research at accelerators. To this aim, the successful
model of the large high-energy physics experiment could be
also adopted in the applied nuclear physics community. The
International Biophysics Collaboration [37] has the ambition
and the potentiality to provide such a network to foster
collaborations, exchange of hardware, design of innovative
research programs, and support for funding applications. Such a
large collaboration will help research at accelerators to maintain
its extraordinary role as a nuclear physics tool for biology
and medicine.
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